The HypoPARAthyroidism Association has had multiple discussions with Takeda regarding the recall of Natpara. While the press releases and patient/doctor letters cover all of the current information, there are a few recurring questions that we would like to specifically address.
Natpara is the same in all markets, but the recall only impacts US Natpara. When the quality issue was discovered, all health authorities were notified. Discussions with FDA resulted in the US recall. Takeda is working with FDA to develop a plan to reestablish drug supply as quickly as possible. At this time, there is no target date, but Takeda is actively working with FDA and has committed to us that patients will remain informed along the way. Written communications have gone out to patients, physicians and pharmacies and case managers have begun making calls. Patients are urged to communicate with their prescribing physicians as soon as possible to develop a plan for discontinuation of Natpara. We understand that treatment plans will be variable between patients, but we are considering some ways that The Association can support patients and physicians throughout this transition process.
The HypoPARAthyroidism Association will continue to have frequent communications with Takeda and with our members. We will share information publicly as it is available and will continue to evaluate how we can best serve the community as the situation evolves. As always, please feel free to communicate directly to the Association with any comments, questions or suggestions.